FBXW7 R505C

CI-VAR-00003863Explore in graph →NP_361014.1:p.Arg505CysNM_033632.3:c.1513C>TClinVar 69961 CIViC 1503 rs149680468

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm1
FBXW7 R505C	Regorafenib Anhydrous	Predictive	D	Supports Resistance	—	submitted	EID4470 In an in vitro study of 16 cancer cell lines, FBXW7 (FBW7) mutant colorectal cancer cell lines (n=8), including LoVo cell line harboring FBW7 R505C mutation, were associated with resistance to regoraf… (full text at CIViC) PMID 27399335 · Tong et al., 2017 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
69961	Likely pathogenic	criteria provided, single submitter	1	FBXW7-related neurodevelopmental disorder; Medulloblastoma WNT activated; Medulloblastoma non-WNT/non-SHH group 3; Embryonal rhabdomyosarcoma; Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype; Alveolar rhabdomyosarcoma	germline/somatic	2	—